Abbott Laboratories (ABT) DIvidends Date & History

Key Takeaways

• Dividend Yield: Abbott Laboratories (ABT) offers an annual dividend of $2.52 per share, translating to a dividend yield of approximately 2.0%, based on recent trading levels.
• Dividend King Status: The company has raised its dividend for 54 consecutive years, placing it firmly among the elite group of Dividend Kings — companies with at least 50 years of uninterrupted annual dividend increases.
• Strong Cash Flow Coverage: Abbott generated $6.35 billion in free cash flow (FCF) in 2024 against $3.84 billion in dividend payments, resulting in a comfortable FCF payout ratio of approximately 60%.
• Consistent Quarterly Payouts: Abbott has paid 407+ consecutive quarterly dividends since 1924, reinforcing a century-long tradition of returning capital to shareholders.
• Modest Yield, Robust Growth: While the current yield is not among the highest in the healthcare sector, Abbott's five-year dividend growth rate of approximately 10.4% annually makes it attractive for dividend growth investors.

Dividend Overview

ABT is a global healthcare leader operating across diagnostics, medical devices, nutritional products, and branded generic pharmaceuticals. The company pays a quarterly dividend of $0.63 per share — recently raised by 6.8% from the prior rate of $0.59 — equating to an annualized payout of $2.52 per share. At recent stock price levels, this translates to a dividend yield near 2.0%, which is modest but consistent with Abbott's profile as a dividend growth stock rather than a high-yield play. Dividends are paid quarterly, with the most recent ex-dividend date on July 15, 2026, and the corresponding payment scheduled for August 17, 2026. Abbott is a member of the S&P 500 Dividend Aristocrats Index, an elite benchmark tracking companies that have increased dividends for at least 25 consecutive years.

Dividend History and Growth

Abbott Laboratories has one of the most impressive dividend track records in corporate America. The company has delivered 54 consecutive years of annual dividend increases, qualifying it as a Dividend King — a designation reserved for companies with at least half a century of uninterrupted dividend growth. Beyond annual increases, Abbott has paid 407 consecutive quarterly dividends since 1924, a streak spanning more than a century. The quarterly dividend has grown more than 70% since 2020, when the payout stood at $0.36 per share. Recent annual increases include a hike from $0.55 to $0.59 in early 2025 and a further increase to $0.63 announced in December 2025 — a 6.8% raise. Over the past five years, Abbott's dividend per share has grown at a compound annual growth rate (CAGR) of roughly 10.4%, reflecting strong underlying earnings momentum and management's commitment to returning capital to shareholders.

Dividend Sustainability and Payout Ratio

Abbott's dividend appears well-supported by both earnings and free cash flow. The company's earnings-based payout ratio stands at approximately 62–67%, a level that leaves ample room for reinvestment in research and development, acquisitions, and debt management. More importantly, Abbott generated $6.35 billion in free cash flow during 2024, while total dividend payments reached $3.84 billion — a free cash flow payout ratio of about 60%. In the third quarter of 2025, the company paid $1.03 billion in dividends while generating $2.29 billion in free cash flow, a quarterly FCF coverage ratio of approximately 45%. Abbott's balance sheet further supports dividend sustainability: the company maintains a debt-to-equity ratio of approximately 0.27, reflecting conservative leverage. With approximately $7.3 billion in cash on hand and disciplined capital expenditures running at roughly 25% of operating cash flow, Abbott retains significant financial flexibility to continue raising its dividend.

Dividend Compared to Industry Peers

Within the healthcare and medical device sector, Abbott's dividend yield of roughly 2.0% sits somewhat below peers such as JNJ (Johnson & Johnson) and MDT (Medtronic), which typically offer yields in the 3.0%–3.5% range. However, Abbott's 54-year growth streak is longer than most healthcare peers and places it in a more exclusive category of dividend reliability. Where Abbott distinguishes itself is in dividend growth: its five-year dividend CAGR of approximately 10.4% outpaces many higher-yielding healthcare peers. This profile — lower current yield but faster dividend growth — is characteristic of companies that prioritize reinvestment in high-return business segments alongside consistent shareholder returns. For investors weighing total return potential, Abbott's combination of a durable competitive moat in medical devices, diagnostics, nutrition, and branded generics supports sustained dividend expansion over the long term.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform designed to help traders and investors filter the market based on technical patterns, fundamental metrics, volatility profiles, and AI-driven trading signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry classification, market capitalization, technical indicators, price patterns, and performance metrics. For dividend-focused investors, the AI Screener can help identify income-generating stocks, dividend growth candidates, and breakout opportunities far more efficiently than manual screening. Whether you are searching for the next Dividend Aristocrat or evaluating income-oriented trades, the AI Screener offers a powerful, data-driven starting point for your research.

Is This Stock Attractive for Dividend Investors?

Abbott Laboratories is best suited for dividend growth investors and long-term, total-return-oriented investors rather than those seeking high current income. With a yield around 2.0%, ABT does not compete with higher-yielding healthcare names or traditional income vehicles. However, its 54-year dividend growth streak, robust free cash flow coverage, and diversified healthcare portfolio make it a compelling candidate for investors who prioritize dividend reliability and compounding growth over time. The company's exposure to structural healthcare trends — including diabetes care, cardiovascular devices, and diagnostic testing — provides a durable revenue foundation that supports continued dividend expansion. Conservative investors may appreciate Abbott's low debt levels and disciplined capital allocation, which reduce the risk of a dividend cut during economic downturns. For those building a portfolio around dividend growth compounding, Abbott's track record of delivering annual increases through multiple economic cycles makes it a noteworthy name in the healthcare sector.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations